Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

signaljumper Jul. 1 at 8:00 PM

$TCRX bullish Breakout on the downtrend Channel.

0 · Reply

keywestbitcoin Jul. 1 at 7:33 PM

$TCRX see the breakout ahead, nice!

0 · Reply

Linenes2 Jun. 30 at 7:41 PM

$TCRX worst Ir team ever . Tscan?more like Tscam for me

1 · Reply

Lima2111 Jun. 30 at 5:36 PM

$TCRX what’s happening here? Did they confirm ALLOHA-2 patient dosing enrollment?

1 · Reply

suredubb Jun. 27 at 4:43 AM

$TCRX somebody bought a lot today… that’s not retail.. great time to start a position

0 · Reply

suredubb Jun. 24 at 12:28 AM

$TCRX Wainwright PT $7… drug works amazing and saves lives.. huge market potential and growth.. awesome physician support already.. commercial ready and already used in most transplant centers… easy LTH Great price to scale in

0 · Reply

topstockalerts Jun. 23 at 10:25 PM

$TCRX this stock has become increasingly difficult to ignore.

2 · Reply

Mmmm1319 Jun. 23 at 1:49 PM

$TCRX Waking up?

0 · Reply

suredubb Jun. 23 at 1:39 AM

$TCRX awesome call.. strong language.. management excited and pleased with data increase in analyst PT incoming.. more tutes will be buying

0 · Reply

GamblingFerret Jun. 22 at 8:42 PM

$TCRX Data are promising, the challenge is the pending financing need communicated last year already for additional phase 1 trials. If they make a deal —> Great, but sounded different in today’s call. They do not have the resources for a phase 3 trial right now, something will happen. High risk of dillution. I am at the sideline, hope that I am wrong.

3 · Reply

TScan Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 24, 2026, 7:00 AM EDT - 10 days ago

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 22, 2026, 8:30 AM EDT - 12 days ago

TScan Therapeutics Transcript: KOL event

Jun 22, 2026, 8:30 AM EDT - 12 days ago

TScan Therapeutics Press release: KOL event

Jun 22, 2026, 8:30 AM EDT - 12 days ago

TScan Therapeutics Slides: KOL event

2026-06-22T11:30:05.000Z - 12 days ago

TScan Therapeutics presents data from Cohort C of ALLOHA trial

Jun 22, 2026, 7:00 AM EDT - 12 days ago

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

2026-06-03T14:29:03.000Z - 4 weeks ago

TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing

Jun 3, 2026, 9:19 AM EDT - 4 weeks ago

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

May 20, 2026, 8:30 AM EDT - 6 weeks ago

TScan Therapeutics Transcript: AGM 2026

2026-05-07T07:41:39.000Z - 2 months ago

TScan Therapeutics reports Q1 EPS (22c), consensus (17c)

May 6, 2026, 7:00 AM EDT - 2 months ago

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026, 7:00 AM EDT - 2 months ago

TScan Therapeutics Earnings release: Q1 2026

May 6, 2026, 7:00 AM EDT - 2 months ago

TScan Therapeutics Quarterly report: Q1 2026

Apr 27, 2026, 4:30 PM EDT - 2 months ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

Apr 17, 2026, 8:00 AM EDT - 2 months ago

TScan Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 3:00 PM EDT - 2 months ago

TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 7:00 AM EDT - 3 months ago

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 3 months ago

TScan Therapeutics Proxy statement: Proxy filing

2026-03-05T14:05:02.000Z - 4 months ago

TScan Therapeutics price target raised to $5 from $4 at Wedbush

Mar 4, 2026, 11:50 AM EST - 4 months ago

TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-04T12:11:24.000Z - 4 months ago

TScan Therapeutics reports Q4 EPS (18c), consensus (28c)

2026-03-04T12:10:31.000Z - 4 months ago

TScan Therapeutics sees cash runway into 2H27

Mar 4, 2026, 7:00 AM EST - 4 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 4, 2026, 7:00 AM EST - 4 months ago

TScan Therapeutics Annual report: Q4 2025

Mar 4, 2026, 7:00 AM EST - 4 months ago

TScan Therapeutics Earnings release: Q4 2025

Mar 4, 2026, 7:00 AM EST - 4 months ago

TScan Therapeutics Slides: Corporate presentation

2026-02-26T12:36:57.000Z - 4 months ago

TScan Therapeutics completes enrollment into Cohort C of ALLOHA study

Feb 26, 2026, 7:00 AM EST - 4 months ago

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Feb 25, 2026, 7:00 AM EST - 4 months ago

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Dec 8, 2025, 8:00 AM EST - 7 months ago

TScan Therapeutics Transcript: KOL Event

Dec 8, 2025, 8:00 AM EST - 7 months ago

TScan Therapeutics Press release: KOL Event

Dec 8, 2025, 8:00 AM EST - 7 months ago

TScan Therapeutics Slides: KOL Event

2025-12-07T18:30:11.000Z - 7 months ago

TScan Therapeutics announces updated data from ALLOHA Phase 1 trial

Dec 3, 2025, 4:05 PM EST - 7 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Nov 26, 2025, 7:00 AM EST - 7 months ago

TScan Therapeutics Slides: Corporate Presentation

2025-11-14T00:55:25.000Z - 8 months ago

TScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Nov 12, 2025, 10:00 AM EST - 8 months ago

TScan Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-12T12:10:19.000Z - 8 months ago

TScan Therapeutics reports Q3 EPS (28c), consensus (33c)

Nov 12, 2025, 7:00 AM EST - 8 months ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 8 months ago

TScan Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

TScan Therapeutics Quarterly report: Q3 2025

Nov 9, 2025, 6:00 PM EST - 8 months ago

TScan Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 7:00 AM EST - 8 months ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

2025-11-04T11:16:37.000Z - 8 months ago

TScan Therapeutics downgraded to Neutral from Buy at BTIG

2025-11-04T11:10:09.000Z - 8 months ago

TScan Therapeutics downgraded to Neutral from Buy at BTIG

2025-11-03T19:05:38.000Z - 8 months ago

TScan Therapeutics price target lowered to $6 from $9 at Needham

Nov 3, 2025, 8:00 AM EST - 8 months ago

TScan Therapeutics Transcript: FDA Announcement

Nov 3, 2025, 8:00 AM EST - 8 months ago

TScan Therapeutics Press release: FDA Announcement

Nov 3, 2025, 8:00 AM EST - 8 months ago

TScan Therapeutics Slides: FDA Announcement

2025-11-03T11:50:39.000Z - 8 months ago

TScan Therapeutics to reduce workforce by 30%

Nov 3, 2025, 6:30 AM EST - 8 months ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 10, 2025, 9:00 AM EDT - 10 months ago

TScan Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 5:35 PM EDT - 10 months ago

TScan Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

2025-08-12T11:05:34.000Z - 11 months ago

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

2025-08-12T11:05:19.000Z - 11 months ago

TScan Therapeutics expects cash to fund operations into Q1 of 2027

Aug 12, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Earnings release: Q2 2025

Jun 4, 2025, 4:55 PM EDT - 1 year ago

TScan Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 1 year ago

TScan Therapeutics Proxy statement: Proxy Filing

May 14, 2025, 8:00 AM EDT - 1 year ago

TScan Therapeutics Proxy statement: Proxy Filing

May 13, 2025, 6:40 PM EDT - 1 year ago

TScan Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

2025-05-12T19:00:24.000Z - 1 year ago

TScan Therapeutics management to meet virtually with BTIG

2025-05-07T10:16:13.000Z - 1 year ago

TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright

2025-05-06T11:06:17.000Z - 1 year ago

TScan Therapeutics reports Q1 EPS (26c), consensus (28c)

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Earnings release: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Slides: Q1 2025

Apr 28, 2025, 4:53 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Apr 7, 2025, 9:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 5, 2025, 1:10 PM EST - 1 year ago

TScan Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Annual report: Q4 2024

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Registration statement: Registration Filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 10:00 AM EST - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Transcript: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Press release: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Slides: Status Update

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 12, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Sep 10, 2024, 9:00 AM EDT - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Earnings release: Q2 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Slides: Company Presentation

Jun 14, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 30, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Proxy statement: Proxy Filing

Apr 30, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 4:05 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 2 years ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 2 years ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 2 years ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 2 years ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 2 years ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Earnings release: Q4 2023

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Annual report: Q4 2023

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Registration statement: Registration Filing

Feb 28, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

signaljumper Jul. 1 at 8:00 PM

$TCRX bullish Breakout on the downtrend Channel.

0 · Reply

keywestbitcoin Jul. 1 at 7:33 PM

$TCRX see the breakout ahead, nice!

0 · Reply

Linenes2 Jun. 30 at 7:41 PM

$TCRX worst Ir team ever . Tscan?more like Tscam for me

1 · Reply

Lima2111 Jun. 30 at 5:36 PM

$TCRX what’s happening here? Did they confirm ALLOHA-2 patient dosing enrollment?

1 · Reply

suredubb Jun. 27 at 4:43 AM

$TCRX somebody bought a lot today… that’s not retail.. great time to start a position

0 · Reply

suredubb Jun. 24 at 12:28 AM

0 · Reply

topstockalerts Jun. 23 at 10:25 PM

$TCRX this stock has become increasingly difficult to ignore.

2 · Reply

Mmmm1319 Jun. 23 at 1:49 PM

$TCRX Waking up?

0 · Reply

suredubb Jun. 23 at 1:39 AM

$TCRX awesome call.. strong language.. management excited and pleased with data increase in analyst PT incoming.. more tutes will be buying

0 · Reply

GamblingFerret Jun. 22 at 8:42 PM

3 · Reply

Rjinvestments88 Jun. 22 at 7:16 PM

$TCRX so all positive no negative 👀 🤔 Commercial-ready TSC-101 manufacturing success in 17 of 19 Cohort C patients (~90%) 14 of 19 patients proceeded to allo-HCT and received a first TSC-101 infusion 11 of 14 patients achieved complete donor chimerism within ~3 weeks after first infusion All 5 patients assessed after a second TSC-101 infusion had complete chimerism TSC-101 reported as generally well-tolerated with safety consistent with Cohort A Company remains on track to begin pivotal Phase 3 ALLOHA-2 enrollment this month

1 · Reply

ducruacuteo11 Jun. 22 at 4:25 PM

$TCRX I waited all of this time for this? LOL. WTF?

0 · Reply

14kmaker Jun. 22 at 3:42 PM

$TCRX this thing will wake up, more news coming this week. Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of 2026

0 · Reply

Jyoudoit Jun. 22 at 3:08 PM

$TCRX WTF is wrong with this stock😡

0 · Reply

durocali Jun. 22 at 11:33 AM

$TCRX https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-positive-initial-data-from-cohort-c-of-oj3vilv79red.html

0 · Reply

durocali Jun. 22 at 11:31 AM

$TCRX company also has $110M cash on hand vs. $60M mk cap. watching this one closely..

1 · Reply

durocali Jun. 22 at 11:26 AM

$TCRX is this a real diamond in the rough? very low volume... needs to pick up.

0 · Reply

Mmmm1319 Jun. 22 at 11:21 AM

$TCRX Patience sir. I agree very bullish. This is not a heavily followed stock. It will climb

1 · Reply

Jyoudoit Jun. 22 at 11:08 AM

$TCRX why is it nit climbing!!!! Its such a heavy bullish result!

0 · Reply

14kmaker Jun. 19 at 12:13 AM

$TCRX some buys that might turn some heads after hours Expecting big moves Monday

0 · Reply

suredubb Jun. 18 at 5:29 PM

$TCRX MMs love to raid stop losses.. scalpers need to make money also tutes are loading up at these prices.. this price action destroys retail…great time to scale in

0 · Reply

OracleObelisk Jun. 18 at 12:54 AM

$TCRX Lead asset is already in clinical trials^^

0 · Reply

Market Cap	69.27M
Revenue (ttm)	10.33M
Net Income (ttm)	-129.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,256.24%
Debt to Equity Ratio	0.34

Volume	879,500
Avg Vol	678,012
Day's Range	N/A - N/A
Shares Out	65.35M
Stochastic %K	80%
Beta	1.04
Analysts	Strong Sell
Price Target	$6.80